Serum miR-204 is an early biomarker of type 1 diabetes-associated pancreatic beta-cell loss. Academic Article uri icon

Overview

abstract

  • Pancreatic beta-cell death is a major factor in the pathogenesis of type 1 diabetes (T1D), but straightforward methods to measure beta-cell loss in humans are lacking, underlining the need for novel biomarkers. Using studies in INS-1 cells, human islets, diabetic mice, and serum samples of subjects with T1D at different stages, we have identified serum miR-204 as an early biomarker of T1D-associated beta-cell loss in humans. MiR-204 is a highly enriched microRNA in human beta-cells, and we found that it is released from dying beta-cells and detectable in human serum. We further discovered that serum miR-204 was elevated in children and adults with T1D and in autoantibody-positive at-risk subjects but not in type 2 diabetes or other autoimmune diseases and was inversely correlated with remaining beta-cell function in recent-onset T1D. Thus, serum miR-204 may provide a much needed novel approach to assess early T1D-associated human beta-cell loss even before onset of overt disease.

publication date

  • August 13, 2019

Research

keywords

  • Biomarkers
  • Diabetes Mellitus, Type 1
  • Insulin-Secreting Cells
  • MicroRNAs

Identity

PubMed Central ID

  • PMC6842918

Scopus Document Identifier

  • 85072993631

Digital Object Identifier (DOI)

  • 10.1038/nm.3287

PubMed ID

  • 31408375

Additional Document Info

volume

  • 317

issue

  • 4